Darwish @darwish@qoto.org

Danicamtiv, a novel cardiac myosin activator, improved left ventricular systolic function and left atrial volume and function for patients with HF with reduced ejection fraction in a phase 2a trial.This randomized, double-blind, placebo-controlled trial was presented at the European Society of Cardiology’s Heart Failure Association Discoveries online event and simultaneously published in

There were fewer spontaneous MIs with revascularization over medical therapy, but at a cost of more procedural infarctions.

The CDC broadened its warning about who is at risk of developing severe disease from Covid-19 infection, suggesting even younger people who are obese or have other health conditions can become seriously ill if they contract the virus.

Whatever you do, never compare their stressful day to yours.

FDA-mandated cardiovascular outcomes trial for a fourth SGLT2 inhibitor, ertugliflozin, confirmed what other drugs in the class had shown.

Sarah Kohnstamm, MD

The post hoc results still need prospective validation but offer hints that PET could play a bigger role in MI prediction.

Greater physical activity may be associated with reduced risk for heart failure in several high-risk subgroups.

It will be important to follow this data in more contemporary cases as TAVR moves to lower-risk patients, the lead author says.

The data confirm earlier reports and show that these patients are at an increased risk of dying in the hospital.

Results from the Global SYMPLICITY Registry found that renal denervation conferred consistent BP reduction in patients with high-risk comorbidities regardless of their atherosclerotic CVD risk score. “These findings reaffirm the efficacy and safety documented in the randomized, sham-controlled trials and extend these results to patients with various comorbidities and high cardiovascular

Fruit fly study reveals role of the gut in causing death by sleep deprivation

Find useful links to resources and tools on this page.

he early period (6 months after index discharge), and 98 were followed during the late period (6–12 months following index discharge). Of them, 46% were on beta-blocker (BB), 49% on angiotensin-converting enzyme inhibitor (ACEi) and/or angiotensin II receptor blocker (ARB), and 51% on aldosterone antagonist at baseline. Prevalence of BB and ACEi/ARB use increased during the study period. During the early period, similar event rates were found irrespective of the NHB uses. During the late period, BB was associated with reduced HF readmission, and ACEi/ARB was associated with reduced HF readmission and gastrointestinal bleeding (p < 0.05 for all). In conclusion, BB and ACEi/ARB use during the late period was associated with a reduction in HF recurrence in LVAD patients. Further prospective randomized control trials are warranted to clarify the utility of NHB therapy in LVAD patients. Submitted for consideration July 2019; accepted for publication in revised form October 2019. T.I. receives financial funding from Postdoctoral Fellowship for Research Abroad of Japan Society for the Promotion of Science. N.U. receives consultant fee and grants support from Abbott and Medtronic. G.S. receives consultant fees from Medtronic. V.J. receives consultant fee from Abbott. The other authors have no conflicts of interest to report. Supplemental digital content is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML and PDF versions of this article on the journal’s Web site (www.asaiojournal.com). This study was presented at the 2018 ISHLT Annual Meeting as a full oral presentation. Correspondence: Nir Uriel, MD, MSc, Department of Medicine, University of Chicago Medical Center, 5841 S. Maryland Avenue, Chicago, IL 60637.Email: nuriel@medicine.bsd.uchicago.edu. Copyright © 2020 by the American Society for Artificial Internal Organs...

Proof-of-concept study showed impact on objective, subjective measures